Federal Register / Vol. 72, No.
223 / Tuesday, November 20, 2007 / Notices
GENERAL SERVICES
ADMINISTRATION
[OMB Control No. 3090–0221]
Civilian Board of Contract Appeals;
Information Collection; Civilian Board
of Contract Appeals Rules of
Procedure
AGENCY: Civilian Board of Contract
Appeals, GSA.
ACTION: Notice of request for comments
regarding a revision to an existing OMB
clearance.
SUMMARY: Under the provisions of the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35), the General Services
Administration will be submitting to the
Office of Management and Budget
(OMB) a request to review and approve
an extension of a currently approved
information collection requirement
regarding the Civilian Board of Contract
Appeals (CBCA) Rules of Procedure.
The clearance currently expires on
January 31, 2008.
Public comments are particularly
invited on: Whether this collection of
information is necessary and whether it
will have practical utility; whether our
estimate of the public burden of this
collection of information is accurate and
based on valid assumptions and
methodology; and ways to enhance the
quality, utility, and clarity of the
information to be collected.
DATES: Submit comments on or before:
January 22, 2008.
FOR FURTHER INFORMATION CONTACT:
Margaret S. Pfunder, Chief Counsel,
Civilian Board of Contract Appeals,
1800 F Street, NW., Washington, DC
20405, telephone (202) 606–8800 or via
e-mail to Margaret.Pfunder@gsa.gov.
ADDRESSES: Submit comments regarding
this burden estimate or any other aspect
of this collection of information,
including suggestions for reducing this
burden to the Regulatory Secretariat
(VIR), General Services Administration,
Room 4035, 1800 F Street, NW.,
Washington, DC 20405. Please cite OMB
Control No. 3090–0221, Civilian Board
of Contract Appeals Rules Procedure, in
all correspondence.
SUPPLEMENTARY INFORMATION:
A. Purpose
The CBCA requires the information
collected in order to conduct
proceedings in contract appeals and
petitions, and cost applications. Parties
include those persons or entities filing
pwalker on PROD1PC71 with NOTICES
appeals, petitions, cost applications,
and government agencies.
B. Annual Reporting Burden
Respondents: 55.
VerDate Aug<31>2005 17:01 Nov 19, 2007 Jkt 214001
65341
Responses Per Respondent: 1.
Hours Per Response: .117.
Total Burden Hours: 6.4.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat (VIR), 1800 F
Street, NW., Room 4035, Washington,
DC 20405, telephone (202) 501–4755.
Please cite OMB Control No. 3090–0221,
Civilian Board of Contract Appeals
Rules of Procedure, in all
correspondence.
Dated: October 30, 2007
Casey Coleman,
Chief Information Officer.
[FR Doc. E7–22603 Filed 11–19–07; 8:45 am]
BILLING CODE 6820–AL–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood Safety and Availability
AGENCY: Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood Safety
and Availability (ACBSA) will hold a
meeting. The meeting will be open to
the public.
DATES: The meeting will take place
Wednesday, January 9, 2008 and
Thursday, January 10, 2008 from 9 a.m.
to 5 p.m.
ADDRESSES: The Westin Washington, DC
City Center, 1400 M Street, NW.,
Washington, DC 20005. Phone: (202)
429–1700.
FOR FURTHER INFORMATION CONTACT: Jerry
A. Holmberg, PhD, Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Room 250, Rockville, MD
20852, (240) 453–8803, Fax (240) 453–
8456, e-mail ACBSA@hhs.gov.
SUPPLEMENTARY INFORMATION: Since the
early 1980s there has been a heightened
awareness of transfusion and
transplantation safety. The formation of
the ACBSA directly resulted out of
concern regarding infectious diseases
and the safety of the blood supply. At
this session of the ACBSA, the
Committee will discuss further safety
developments to enhance transfusion
and transplantation safety. These
discussions will include the current
PO 00000 Frm 00054 Fmt 4703 Sfmt 4703
landscape and residual risk of known
and unknown pathogens. In addition,
the Committee will look at needs and
barriers to potential opportunities in
donor screening and technologies for
pathogen reduction.
The public will be given opportunity
to provide comments to the Committee
on January 9 and 10, 2008. Comments
will be limited to five minutes per
speaker. Anyone planning to comment
is encouraged to contact the Executive
Secretary at his/her earliest
convenience. Those who wish to have
printed material distributed to Advisory
Committee members should submit, at a
minimum, one copy of the material, to
the Executive Secretary prior to close of
business January 7, 2008. Likewise,
those who wish to utilize electronic data
projection to the Committee must
submit their materials to the Executive
Secretary prior to close of business
January 7, 2008.
Dated: November 13, 2007.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on
Blood Safety and Availability.
[FR Doc. E7–22653 Filed 11–19–07; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0220]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Animal Drug User
Fee Cover Sheet, FDA Form 3546
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by December
20, 2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0539. Also
E:\FR\FM\20NON1.SGM 20NON1